Official Title
Regional Registry-based Biobank Development and Pharmacogenetic Analysis: Synergistic Strategies Driving Towards Personalized Medicine in Rheumatoid Arthritis Management
Brief Title
Regional Registry-based Biobank Development and Pharmacogenetic Analysis in Rheumatoid Arthritis
Protocol ID
NCT03555240
Lead Sponsor
Istituto Ortopedico Rizzoli
Brief Summary
Aim of this project is the building-up of an integrated model of multidisciplinary
research tools to support large-scale and high-quality disease-based studies.
Detailed Description
Biologics have revolutionized rheumatoid arthritis (RA) management, with a great impact
on patient that justifies treatment with these high-cost drugs. Nevertheless, timing and
proper therapeutic decision making remain the main challenge in clinical practice.
Pharmacogenetics approach might open promising perspectives, increasing our understanding
on genetic-related drug efficacy. Nevertheless, to ensure feasibility and reliability of
translational applications of this strategy in clinical practice, large population-based
research studies represent a crucial key step.
Objectives
Major aim of this project is the building-up of an integrated model of multidisciplinary
research tools to support large-scale and high-quality disease-based studies. The main
targets of this proposal will be:
- to develop a disease-based biobank, integrated with already established
Emilia-Romagna regional RA Registry, providing a large-scale prospective collection
and storing of multiple biological samples
- to perform a pharmacogenetic study analyzing a panel of gene variants potentially
influencing the response to Tumor Necrosis Factor (TNF) blockers. Methods
- Biobank development. A step-wise plan will be considered for: designing biobank
governance frame-work, defining Standard Operating Procedures, implementing
information system resources. All these procedures will be applied for collecting,
processing and storing biological samples of patients included in regional RA
registry.
- Pharmacogenetic study. A panel of candidate gene variants will be studied in genomic
DNA from 300 patients enrolled in the regional RA registry. The association between
genotypes and response to biological drugs will be assessed by data-mining approach,
and a predictive model will be defined. Expected Results This proposal will create a
disease-based biobank, tightly integrated with the already established
Emilia-Romagna regional RA Registry, and pave the way towards personalized therapy
applications in Rheumatology.
Study Period
-
Enrollment Count
600 participants
Eligibility Criteria
Inclusion Criteria:
1. Diagnosis of Arthritis Rheumatoid according American College of Rheumatology
(ACR)1987 or according ACR/European League Against Rheumatism (EULAR) 2010 criteria
2. Patients with new diagnosis or patients already diagnosed with active disease [with
Disease Activity Score (DAS) 28 > o = 4,2] or patients switching therapy
3. Male and female patients of minimum 18 years old
4. Provision of informed consent
Exclusion Criteria:
1) Patients living outside Emilia Romagna region
Filters
Rheumatoid Arthritis
COMPLETED
ADULT
OLDER_ADULT